Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimicotinib PK in Hepatic Impairment
NCT06562946Phase 1Completed
- Sponsor
- Abbisko Therapeutics
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pimicotinib in tenosynovial giant cell tumor (TGCT) (3 arms), sponsored by Abbisko Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Area Under the Curve from Time Zero to Last Quantifiable Concentration at 48 hours and 1 more. Started Sep 2024; status: completed.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT06562946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06562946.